Potentially universal, broadly protective, or next-generation influenza vaccine candidates are in phase 1 trials.
A large and diverse group of candidates are in active preclinical development.
Milestone
4.2.c
Early clinical evaluation
Completed
High priority
Identify an initial set of vaccine candidates that demonstrate broad-based immunity—humoral, cell-mediated, or both—in preclinical research and assess them for safety and immunogenicity in phase 1 clinical trials in healthy adults.